Year Book of Oncology 2011

1. Cover - p. 1 2. Contents - p. 2 3. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma - p. 6 4. Weight Lifting for Women at Risk for Breast Cancer–Related Lymphedema: A Randomized Trial - p. 7 5. Effect of Active Resistive Exercise on Breast Cancer–Related Lymphedema: A Randomized Controlled Trial - p. 8 6. Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies - p. 9 7. Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer - p. 10 8. Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies - p. 11 9. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature - p. 12 10. 17ß-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer - p. 13 11. Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association with Responsiveness to Anthracycline-Based Chemotherapy - p. 14 12. Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials - p. 15 13. HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients - p. 16 14. Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer - p. 17 15. Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer - p. 18 16. Pathologic Complete Response in Breast Cancer Patients Receiving Anthracycline- and Taxane-Based Neoadjuvant Chemotherapy: Evaluating the Effect of Race/Ethnicity - p. 19 17. Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer - p. 20 18. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009) - p. 21 19. Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial - p. 22 20. Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15 Years of Follow-Up - p. 23 21. Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens - p. 24 22. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer - p. 25 23. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study - p. 26 24. Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases - p. 27 25. Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer - p. 28 26. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial - p. 29 27. Breast MRI Screening of Women With a Personal History of Breast Cancer - p. 30 28. Breast MRI After Conservation Therapy: Usual Findings in Routine Follow-Up Examinations - p. 31 29. Axillary Ultrasound and Fine-Needle Aspiration in the Preoperative Evaluation of the Breast Cancer Patient: An Algorithm Based on Tumor Size and Lymph Node Appearance - p. 32 30. Effect of Screening Mammography on Breast-Cancer Mortality in Norway - p. 33 31. Update on DCIS Outcomes from the American Society of Breast Surgeons Accelerated Partial Breast Irradiation Registry Trial - p. 35 32. Effect of Radiotherapy Boost and Hypofractionation on Outcomes in Ductal Carcinoma In Situ - p. 36 33. Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biopsy - p. 38 34. Breast Cancer Subtypes and the Risk of Local and Regional Relapse - p. 39 35. Symptoms 10–17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial - p. 41 36. Long-Term Cardiovascular Mortality After Radiotherapy for Breast Cancer - p. 43 37. Coverage of axillary lymph nodes with high tangential fields in breast radiotherapy - p. 44 38. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality - p. 45 39. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial - p. 46 40. Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study - p. 47 41. “Primary peritoneal” high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: Assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer - p. 48 42. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q) - p. 49 43. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer - p. 50 44. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer - p. 51 45. Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer - p. 52 46. Clinical Outcome of Tertiary Surgical Cytoreduction in Patients with Recurrent Epithelial Ovarian Cancer - p. 53 47. Clinical predictors of bevacizumab-associated gastrointestinal perforation - p. 54 48. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial - p. 55 49. Development of a Multimarker Assay for Early Detection of Ovarian Cancer - p. 56 50. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group - p. 57 51. Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial - p. 58 52. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers - p. 59 53. Ovarian cancer patient surveillance after curative-intent initial treatment - p. 60 54. Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial - p. 61 55. The Use of Recombinant Erythropoietin for the Treatment of Chemotherapy-Induced Anemia in Patients With Ovarian Cancer Does Not Affect Progression-Free or Overall Survival - p. 62 56. Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: A phase II trial - p. 63 57. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study - p. 64 58. Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix - p. 65 59. A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: A Kansai Clinical Oncology Group study (KCOG0015 trial) - p. 66 60. CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer - p. 67 61. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group Study - p. 68 62. Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer: A Decision Analysis - p. 69 63. Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer - p. 70 64. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer - p. 71 65. Do Anxiety and Distress Increase During Active Surveillance for Low Risk Prostate Cancer? - p. 72 66. Effect of Dutasteride on the Risk of Prostate Cancer - p. 73 67. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study - p. 74 68. Natural History of Clinically Staged Low- and Intermediate-Risk Prostate Cancer Treated With Monotherapeutic Permanent Interstitial Brachytherapy - p. 75 69. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer - p. 76 70. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer - p. 77 71. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer - p. 78 72. Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09 - p. 79 73. Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer - p. 80 74. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose–response analysis - p. 81 75. Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy - p. 82 76. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients - p. 83 77. Time of decline in sexual function after external beam radiotherapy for prostate cancer - p. 84 78. Evaluation of late adverse events in long-term Wilms' tumor survivors - p. 85 79. Racial Differences in Treatment and Outcomes Among Patients With Early Stage Bladder Cancer - p. 86 80. Radiation dose–volume effects of the urinary bladder - p. 87 81. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia - p. 88 82. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1 - p. 89 83. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study - p. 90 84. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group - p. 91 85. Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study - p. 92 86. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling - p. 93 87. Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells - p. 94 88. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia - p. 95 89. Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial - p. 96 90. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias - p. 97 91. Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia - p. 98 92. Prognostic Importance of Histone Methyltransferase MLL5 Expression in Acute Myeloid Leukemia - p. 99 93. 6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1 - p. 100 94. AIDA0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance - p. 101 95. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood - p. 102 96. Analysis of the Role of Hematopoietic Stem-Cell Transplantation in Infants With Acute Lymphoblastic Leukemia in First Remission and MLL Gene Rearrangements: A Report From the Children's Oncology Group - p. 103 97. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial - p. 104 98. Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes - p. 105 99. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis - p. 106 100. Demographic, clinical and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial - p. 107 101. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial - p. 108 102. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles - p. 109 103. Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia - p. 110 104. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors - p. 111 105. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group - p. 112 106. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study - p. 113 107. Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881 - p. 114 108. RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group - p. 115 109. Secondary solid cancers after allogeneic hematopoietic-cell transplantation using busulfan-cyclophosphamide conditioning - p. 116 110. Autoimmune Lymphoproliferative Syndrome Like Disease With Somatic KRAS Mutation - p. 117 111. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice - p. 118 112. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study - p. 119 113. Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma - p. 120 114. Pleural fluid analysis of lung cancer vs benign inflammatory disease patients - p. 121 115. ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non–Small-Cell Lung Cancer: Expert Panel on Radiation Oncology–Lung - p. 122 116. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer - p. 123 117. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117 - p. 124 118. Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599 - p. 125 119. Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer - p. 126 120. A Phase 2 Study of Irinotecan, Cisplatin, and Simvastatin for Untreated Extensive-disease Small Cell Lung Cancer - p. 127 121. Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial - p. 128 122. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning - p. 129 123. Lung cancer in ‘Never-smokers’: a unique entity - p. 130 124. Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324 - p. 131 125. Bronchopulmonary Carcinoid Tumors: Long-Term Outcomes After Resection - p. 132 126. Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer - p. 133 127. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial - p. 134 128. A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma - p. 135 129. A Phase 2 Trial of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma: Cancer and Leukemia Group B (CALGB) 80003 - p. 136 130. Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2 - p. 137 131. Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes - p. 138 132. Radiation dose–volume effects in radiation-induced rectal injury - p. 139 133. Association Between Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer: A Systematic Review and Meta-Analysis - p. 140 134. DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy - p. 141 135. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial - p. 142 136. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial - p. 143 137. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial - p. 144 138. Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis - p. 145 139. Correlation of Somatic Mutation and Expression Identifies Genes Important in Human Glioblastoma Progression and Survival - p. 146 140. Nuclear ErbB2 Enhances Translation and Cell Growth by Activating Transcription of Ribosomal RNA Genes - p. 147 141. The Genetic Landscape of the Childhood Cancer Medulloblastoma - p. 148 142. Prognostic Factors After Relapse in Nonmetastatic Rhabdomyosarcoma: A Nomogram to Better Define Patients Who Can Be Salvaged With Further Therapy - p. 149 143. Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group - p. 150 144. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group - p. 151 145. A Randomized Phase 2 Study of Etaracizumab, a Monoclonal Antibody Against Integrin αvβ3, ± Dacarbazine in Patients With Stage IV Metastatic Melanoma - p. 152 146. Role of Radiation Therapy in Cutaneous Melanoma - p. 153 147. A Prospective Phase II Evaluation of Esophageal Stenting for Neoadjuvant Therapy for Esophageal Cancer: Optimal Performance and Surgical Safety - p. 154 148. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy - p. 155 149. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning - p. 156 150. Genetic Abnormalities of the EGFR Pathway in African American Patients With Non–Small-Cell Lung Cancer - p. 157 151. Treatment-Related Mortality With Bevacizumab in Cancer Patients: A Meta-analysis - p. 158 152. Randomized comparison of whole brain radiotherapy, 20 Gy in four daily fractions versus 40 Gy in 20 twice-daily fractions, for brain metastases - p. 159 153. Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy - p. 160 154. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer - p. 161 155. Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study - p. 162 156. What Constitutes Reasonable Evidence of Efficacy and Effectiveness to Guide Oncology Treatment Decisions? - p. 163